Food Allergies Are T
Food Allergies Are Top Concern for Families As They Prepare for Back-to-School
August 15, 2019 08:21 ET | Asthma and Allergy Foundation of America
Washington, D.C., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released a report of findings from its “My Life With Food Allergy” study. As children...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
May 17, 2019 13:25 ET | Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
DAO-To-Go
Quick Umbrellux DAO Test Reveals If That Reaction Is Really Histamine Intolerance And Not A Food Allergy
May 13, 2019 09:30 ET | Umbrellux DAO
ANN ARBOR, Mich., May 13, 2019 (GLOBE NEWSWIRE) -- Food Allergy Awareness Week is the perfect time to determine if you may be mislabeling your body’s reaction to certain foods. Umbrellux DAO offers...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET | Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
USBioTekLogo.png
US BioTek Laboratories Announces Jack Frausing as CEO
January 14, 2019 08:00 ET | US BioTek
SEATTLE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- US BioTek Laboratories (US BioTek) announced today the appointment of a new President and CEO, Jack Frausing. Frausing assumes the leadership from...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET | Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
September 06, 2018 07:11 ET | Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 15, 2018 12:00 ET | Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
May 09, 2018 10:36 ET | Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
April 24, 2018 09:27 ET | Intrommune Therapeutics
New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...